These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 29085194)

  • 21. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
    Jadvar H; Henderson RW; Conti PS
    J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of 18F-FDG PET/CT in the evaluation of gastric cancer recurrence after curative gastrectomy.
    Lee JE; Hong SP; Ahn DH; Jeon TJ; Kang MK; Kwon CI; Ko KH; Hwang SG; Park PW; Rim KS
    Yonsei Med J; 2011 Jan; 52(1):81-8. PubMed ID: 21155039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.
    Weber T; Ohlhauser D; Hillenbrand A; Henne-Bruns D; Reske SN; Luster M
    Horm Metab Res; 2012 Nov; 44(12):904-8. PubMed ID: 22791600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study.
    Zattoni F; Incerti E; Colicchia M; Castellucci P; Panareo S; Picchio M; Fallanca F; Briganti A; Moschini M; Gallina A; Karnes JR; Lowe V; Fanti S; Schiavina R; Rambaldi I; Ficarra V; Evangelista L
    Abdom Radiol (NY); 2018 Sep; 43(9):2391-2399. PubMed ID: 29302738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detecting recurrence of gastric cancer: the value of FDG PET/CT.
    Park MJ; Lee WJ; Lim HK; Park KW; Choi JY; Kim BT
    Abdom Imaging; 2009 Jul; 34(4):441-7. PubMed ID: 18543017
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
    Park JW; Jo MK; Lee HM
    BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [18F]Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy.
    Hildebrandt MG; Gerke O; Baun C; Falch K; Hansen JA; Farahani ZA; Petersen H; Larsen LB; Duvnjak S; Buskevica I; Bektas S; Søe K; Jylling AM; Ewertz M; Alavi A; Høilund-Carlsen PF
    J Clin Oncol; 2016 Jun; 34(16):1889-97. PubMed ID: 27001573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peritoneal carcinomatosis in patients with ovarian cancer: enhanced CT versus 18F-FDG PET/CT.
    Kim HW; Won KS; Zeon SK; Ahn BC; Gayed IW
    Clin Nucl Med; 2013 Feb; 38(2):93-7. PubMed ID: 23334121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peritoneal carcinomatosis from ovarian cancer: the role of CT and [¹⁸F]FDG-PET/CT.
    Funicelli L; Travaini LL; Landoni F; Trifirò G; Bonello L; Bellomi M
    Abdom Imaging; 2010 Dec; 35(6):701-7. PubMed ID: 19784697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of ¹⁸F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma after hepatectomy or radiofrequency ablation: a comparative study with contrast-enhanced ultrasound.
    Wang XY; Chen D; Zhang XS; Chen ZF; Hu AB
    J Dig Dis; 2013 Aug; 14(8):433-8. PubMed ID: 23615075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography.
    Jadvar H; Tatlidil R; Garcia AA; Conti PS
    Clin Radiol; 2003 Mar; 58(3):215-21. PubMed ID: 12639527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of FDG-PET/CT in follow-up of patients treated with resective gastric surgery for tumour.
    Graziosi L; Bugiantella W; Cavazzoni E; Cantarella F; Porcari M; Baffa N; Donini A
    Ann Ital Chir; 2011; 82(2):125-9. PubMed ID: 21682102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
    De Potter T; Flamen P; Van Cutsem E; Penninckx F; Filez L; Bormans G; Maes A; Mortelmans L
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):525-9. PubMed ID: 11914891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peritoneal carcinomatosis: role of (18)F-FDG PET.
    Turlakow A; Yeung HW; Salmon AS; Macapinlac HA; Larson SM
    J Nucl Med; 2003 Sep; 44(9):1407-12. PubMed ID: 12960184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis.
    Daamen LA; Groot VP; Goense L; Wessels FJ; Borel Rinkes IH; Intven MPW; van Santvoort HC; Molenaar IQ
    Eur J Radiol; 2018 Sep; 106():128-136. PubMed ID: 30150034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
    Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
    Yun M; Lim JS; Noh SH; Hyung WJ; Cheong JH; Bong JK; Cho A; Lee JD
    J Nucl Med; 2005 Oct; 46(10):1582-8. PubMed ID: 16204706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Peritoneal carcinomatosis from ovarian cancer: role of 18F-FDG-PET/CT and CA125].
    Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Stabile Ianora AA; Giganti M; Niccoli Asabella A
    Recenti Prog Med; 2012 Nov; 103(11):510-4. PubMed ID: 23096741
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDG-PET/CT as a post-treatment restaging tool in urothelial carcinoma: Comparison with contrast-enhanced CT.
    Kitajima K; Yamamoto S; Fukushima K; Yamakado K; Katsuura T; Igarashi Y; Kawanaka Y; Mouri M; Hirota S
    Eur J Radiol; 2016 Mar; 85(3):593-8. PubMed ID: 26860672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.